Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(Suppl 2):247-52
Article Links
The Rheumatologist’s Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future
Christos Koutsianas1, Katerina Chatzidionysiou2
Authors Information

1. Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom
2. Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institute, Stockholm, Sweden

Christos Koutsianas, Katerina Chatzidionysiou

Keywords: Rheumatic diseases, rheumatology, COVID-19, SARS-CoV-2, telemedicine, hyperinflammation
References
  1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395(10223):507-13.
  2. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed April 27, 2020.
  3. Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis 2020 Jul 28;71(15):888-9.
  4. Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med 2020;172(12):819-21.
  5. Shanafelt T, Ripp J, Trockel M. Understanding and Addressing Sources of Anxiety Among Health Care Professionals During the COVID-19 Pandemic. JAMA 2020 Jun 2;323(21):2133-4.
  6. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev March 2020:102523.
  7. Joo Y Bin, Lim Y-H, Kim K-J, Park K-S, Park Y-J. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther 2019;21(1):199.
  8. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 2020 Apr 22;annrheumdis-2020-217615.
  9. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79(5):667-8.
  10. Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol 2020;16(6):293-4.
  11. EULAR Guidance for patients COVID-19 outbreak. Updated 17 March 2020. https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm. Accessed April 29, 2020.
  12. Devadula S, Langbecker D, Vecchio P, Tesiram J, Meiklejohn J, Benham H. Tele-Rheumatology to Regional Hospital Outpatient Clinics: Patient Perspectives on a New Model of Care. Telemed e-Health November 2019:tmj.2019.0111.
  13. Najm A, Nikiphorou E, Kostine M, Richez C, Pauling JD, Finckh A, et al. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open 2019;5(2):e001014.
  14. Marotto D, Sarzi-Puttini P. What is the role of rheumatologists in the era of COVID-19? Autoimmun Rev April 2020:102539.
  15. McInnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis 2020;79(5):551-52.
  16. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970.
  17. Toniati P, Piva S, Cattalini M, Garaffa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19(7):102568.
  18. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms 2020;8(5).
  19. Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19. Accessed June 7, 2020.
  20. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020 Jul;2(7):393-400.
  21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020 Jul 1;180(7):934-43.
  22. U.S. National Library of Medicine. ClinicalTrials.gov Identifier: NCT04244591. Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure. Accessed 2020 Apr 21.
  23. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020;382(17):e38.
  24. Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31(4):213-23.
  25. Chatzidionysiou K, Svenungsson E, Faustini F. Could severe COVID-19 be considered a complementopathy? Lupus Sci Med 2020;7(1):e000415.